A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast

References

• Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34:J314–J321.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. DOI:10.1016/S0140-6736(14)61909-7.
   PubMed Web of Science ®Google Scholar
• Ficco HM, Citera G, Cocco JA. Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clin Rheumatol. 2014;33(10):1489–1493.
   PubMed Web of Science ®Google Scholar
• Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25:524–528.
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
   PubMed Web of Science ®Google Scholar
• Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol. 2005;5:699–711.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Saraceno R, Chimenti MS, et al. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets. 2014;18(5):513–525.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(2):ii30–36.
   PubMedGoogle Scholar
• Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2011;131(3):677–687.
   PubMed Web of Science ®Google Scholar
• Baliwag J, Barnes DH, Johnston A. Cytokines in psoriasis. Cytokine. 2015;73(2):342–350.
   PubMed Web of Science ®Google Scholar
• Man HW, Schafer P, Wong LM, et al. Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor. J Med Chem. 2009;52(6):1522–1524.
   PubMed Web of Science ®Google Scholar
• Limaye K. Psoriasis: an overview and update. Nurse Pract. 2015;40(3):23–26.
   PubMedGoogle Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–867.
   PubMed Web of Science ®Google Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648.
   PubMed Web of Science ®Google Scholar
• Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol. 2010;160(4):810–820.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114–135.
   PubMed Web of Science ®Google Scholar
• Dogra S, Mahajan R. Systemic methotrexate therapy for psoriasis: past, present and future. Clin Exp Dermatol. 2013;38(6):573–588.
   PubMed Web of Science ®Google Scholar
• Colombo MD, Cassano N, Bellia G, et al. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. Sci World J. 2013;2013:1–11.
   Web of Science ®Google Scholar
• Saurat JH. Side effects of systemic retinoids and their clinical management. J Am Acad Dermatol. 1992;27(6 Pt 2):S23–28.
   PubMed Web of Science ®Google Scholar
• Carretero G, Ferrandiz C, Dauden E, et al. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. Eur Acad Dermatol Venereol. 2015;29(1):156–163.
   PubMed Web of Science ®Google Scholar
• Novelli L, Chimenti MS, Chiricozzi A, et al. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev. 2014;13:64–69.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Burden AD, Hilton Boon M, Leman J, et al. Diagnosis and management of psoriasis and psoriatic arthritis in adults: summary of SIGN guidance. BMJ. 2010;341:c5623.
   PubMed Web of Science ®Google Scholar
• Dommasch ED, Troxel AB, Gelfand JM. Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses. J Am Acad Dermatol. 2013;68(5):863–865.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Trigoni A, et al. Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date. Dermatoendocrinol. 2012;4(3):320–323.
   PubMedGoogle Scholar
• Chiricozzi A. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis. Actas Dermosifiliogr. 2014;105(1):9–20.
   PubMedGoogle Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Langley RG, Philipp S, et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol. 2015;14(8):821–833.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Aslam A, Griffiths CE. Drug therapies in dermatology. Clin Med. 2014;14(1):47–53.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol. 2002;138(5):686–688.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014 Aug 1;4(8). pii: a015354. DOI:10.1101/cshperspect.a015354.
   PubMed Web of Science ®Google Scholar
• Kaminska B, Swiatek-Machado K. Targeting signaling pathways with small molecules to treat autoimmune disorders. Expert Rev Clin Immunol. 2008;4:93–112.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015 Feb;95(2):133–139.
   PubMed Web of Science ®Google Scholar
• Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16:443.
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109(3):366–398.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Murata T, Shimizu K, et al. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis. 2015;21(1):e25–50.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cellular Signalling. 2014;26:2016–2029.
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Kilić A, Hoffmann LS. Regulation of metabolism by cGMP. Pharmacol Ther. 2013;140(1):81–91.
   PubMed Web of Science ®Google Scholar
• Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 2014;35(2):195–233.
   PubMed Web of Science ®Google Scholar
• Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099–1108.
   PubMed Web of Science ®Google Scholar
• Mahmood T, Zaghi D, Menter A. Emerging oral drugs for psoriasis. Expert Opin Emerg Drugs. 2015;20(2):209–220.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855.
   PubMed Web of Science ®Google Scholar
• Claveau D, Chen SL, O’Keefe S, et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4- [2 - (3,4 - Bisdifluromethoxyphenyl) - 2 - [4 - (1,1,1,3,3,3 - hexafluoro - 2 - hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther. 2004;310:752–760.
   PubMed Web of Science ®Google Scholar
• Conti M, Richter W, Mehats C, et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem. 2003;278:5493–5496.
   PubMed Web of Science ®Google Scholar
• Odingo JO. Inhibitors of PDE4: a review of recent patent literature. Exp Opin Ther Pat. 2005;15:773–787.
   Web of Science ®Google Scholar
• Calverley PMA, Fabbri LM, Rabe KF, et al. Roflumilast in the treatment of COPD: a pooled safety analysis. Eur Respir J. 2010;36(54):Abstract P4001.
   Google Scholar
• Scanlon PD. The pathogenesis and pathology of COPD: identifying risk factors and improving morbidity and mortality. Adv Stud Med. 2004;4(10A):SS744–S749.
   Google Scholar
• Gottlieb AB, Strober B, Krueger JG, et al. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008;24(5):1529–1538.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12(8):888–897.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016–2029.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Dec 17]. Available from: http://ec.europa.eu/health/documents/community-register/2015/20150115130395/anx_130395_en.pdf
   Google Scholar
• Hoffmann M, Kumar G, Schafer P, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica. 2011;41(12):1063–1075.
   PubMed Web of Science ®Google Scholar
• Schett G, Sloan VS, Stevens RM, et al. Apremilast: A novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis. 2010;2(5):271–278.
   PubMedGoogle Scholar
• Available from: http://www.otezla.com/otezla-prescribing-information.pdf
   Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–1590.
   PubMed Web of Science ®Google Scholar
• Abdulrahim H, Thistleton S, Adebajo AO, et al. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2015;16(7):1099–1108.
   PubMed Web of Science ®Google Scholar
• Papp K, Kaufmann R, Thaçi D, et al. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376–383.
   PubMed Web of Science ®Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738–746.
   PubMed Web of Science ®Google Scholar
• Apremilast: Phase 2,3,4 - List Results. Bethesda (MD): US National Library of Medicine. [cited 2015 Aug 7]. Available from: www.ClinicalTrials.gov.
   Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015 Sep 10;173:1387–1399. DOI:10.1111/bjd.14164. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Reich K, Papp K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 1) [oral]. Oral presented at: 71st Annual Meeting of the American Academy of Dermatology (AAD); 2013 Mar 1–5; Miami Beach, FL.
   Google Scholar
• Paul C, Cather J, Gooderham M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21–25; Denver, CO.
   Google Scholar
• Papp K, Reich K, Leonardi C, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from the randomized treatment withdrawal phase of a phase 3, randomized, controlled trial (ESTEEM 1) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21–25; Denver, CO.
   Google Scholar
• Reich K, Papp K, Leonardi C, et al. Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: results from a phase III, randomized, controlled trial (ESTEEM 1) [poster]. Poster presented at: 72nd Annual Meeting of the American Academy of Dermatology (AAD); 2014 Mar 21–25; Denver, CO.
   Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
   PubMed Web of Science ®Google Scholar
• Reich K, Sobell J, Day R, et al. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Poster 1162. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.
   Google Scholar
• Available from: http://www.otezla.com/wp-content/uploads/2014/05/otezla-prescribing-information.pdf
   Google Scholar
• Houslay MD, Schafer P, Zhang K. Phosphodiesterase-4 as a terapeutic target. Drug Discov Today. 2005;10:1503–1519.
   PubMed Web of Science ®Google Scholar
• Feldam SR, Tencer T, Clancy Z, et al. Cost per responder of apremilast versus etanercept, adalimumab, and ustekinumab in patients with moderate to severe psoriasis. Poster 1108. Presented at the 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20–24; San Francisco, CA.
   Google Scholar
• Danesh MJ, Beroukhim K, Nguyen C, et al. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatol Online J. 2015 Jun 16;21(6). pii: 13030/qt5gf406zs.
   Google Scholar
• Liu Y, Zhou S, Nissel J, et al. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis. Clin Pharmacol Drug Dev. 2014;3(6):456–465.
   PubMed Web of Science ®Google Scholar